Pharming Price To Sales Ratio vs Free Cash Flow Yield Analysis

PHAR Stock  USD 9.32  0.05  0.54%   
Pharming Group financial indicator trend analysis is much more than just breaking down Pharming Group NV prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pharming Group NV is a good investment. Please check the relationship between Pharming Group Price To Sales Ratio and its Free Cash Flow Yield accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Price To Sales Ratio vs Free Cash Flow Yield

Price To Sales Ratio vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pharming Group NV Price To Sales Ratio account and Free Cash Flow Yield. At this time, the significance of the direction appears to have no relationship.
The correlation between Pharming Group's Price To Sales Ratio and Free Cash Flow Yield is 0.08. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of Pharming Group NV, assuming nothing else is changed. The correlation between historical values of Pharming Group's Price To Sales Ratio and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Pharming Group NV are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Price To Sales Ratio i.e., Pharming Group's Price To Sales Ratio and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

0.08
Relationship DirectionPositive 
Relationship StrengthInsignificant

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Pharming Group NV stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Pharming Group sales, a figure that is much harder to manipulate than other Pharming Group NV multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.
Most indicators from Pharming Group's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pharming Group NV current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
At this time, Pharming Group's Selling General Administrative is relatively stable compared to the past year. As of 12/13/2024, Issuance Of Capital Stock is likely to grow to about 4 M, while Tax Provision is likely to drop (1.5 M).
 2021 2022 2023 2024 (projected)
Total Operating Expenses156.7M169.8M225.5M236.8M
Cost Of Revenue20.2M17.6M25.2M15.2M

Pharming Group fundamental ratios Correlations

0.980.920.640.970.90.190.380.230.70.760.96-0.180.980.910.660.580.950.860.620.880.970.990.090.81-0.37
0.980.920.590.920.870.090.390.190.710.770.94-0.210.960.850.610.540.980.850.560.860.980.970.050.83-0.38
0.920.920.680.830.720.190.39-0.010.80.690.9-0.220.90.850.620.540.910.780.560.830.960.910.150.78-0.42
0.640.590.680.520.350.510.17-0.260.670.490.80.060.50.780.250.150.480.410.170.80.720.530.770.86-0.44
0.970.920.830.520.930.190.320.420.590.730.89-0.150.980.860.670.60.880.850.660.810.880.98-0.040.71-0.28
0.90.870.720.350.930.00.330.370.430.680.8-0.230.920.740.630.570.870.830.60.720.810.92-0.180.6-0.25
0.190.090.190.510.190.0-0.31-0.140.280.310.320.050.130.26-0.16-0.20.0-0.16-0.060.410.180.110.390.41-0.12
0.380.390.390.170.320.33-0.310.070.42-0.290.30.10.320.570.870.890.390.670.760.090.410.410.050.12-0.12
0.230.19-0.01-0.260.420.37-0.140.07-0.110.150.090.370.310.130.260.30.150.290.45-0.020.030.3-0.43-0.020.45
0.70.710.80.670.590.430.280.42-0.110.440.70.040.660.690.520.470.70.570.540.70.770.670.20.72-0.27
0.760.770.690.490.730.680.31-0.290.150.440.77-0.30.780.490.04-0.060.750.420.060.830.730.720.010.78-0.32
0.960.940.90.80.890.80.320.30.090.70.77-0.10.890.920.510.420.870.740.480.920.970.90.330.92-0.38
-0.18-0.21-0.220.06-0.15-0.230.050.10.370.04-0.3-0.1-0.24-0.01-0.060.0-0.3-0.170.22-0.29-0.2-0.220.26-0.040.75
0.980.960.90.50.980.920.130.320.310.660.780.89-0.240.830.650.580.950.850.630.830.930.99-0.090.73-0.33
0.910.850.850.780.860.740.260.570.130.690.490.92-0.010.830.750.680.770.840.670.790.90.870.370.77-0.39
0.660.610.620.250.670.63-0.160.870.260.520.040.51-0.060.650.750.990.610.870.910.360.610.72-0.110.24-0.21
0.580.540.540.150.60.57-0.20.890.30.47-0.060.420.00.580.680.990.540.820.930.250.520.65-0.170.15-0.12
0.950.980.910.480.880.870.00.390.150.70.750.87-0.30.950.770.610.540.840.560.810.950.95-0.090.75-0.37
0.860.850.780.410.850.83-0.160.670.290.570.420.74-0.170.850.840.870.820.840.740.630.820.9-0.050.52-0.38
0.620.560.560.170.660.6-0.060.760.450.540.060.480.220.630.670.910.930.560.740.270.530.67-0.20.220.15
0.880.860.830.80.810.720.410.09-0.020.70.830.92-0.290.830.790.360.250.810.630.270.890.830.290.92-0.53
0.970.980.960.720.880.810.180.410.030.770.730.97-0.20.930.90.610.520.950.820.530.890.940.210.87-0.44
0.990.970.910.530.980.920.110.410.30.670.720.9-0.220.990.870.720.650.950.90.670.830.94-0.050.72-0.35
0.090.050.150.77-0.04-0.180.390.05-0.430.20.010.330.26-0.090.37-0.11-0.17-0.09-0.05-0.20.290.21-0.050.47-0.27
0.810.830.780.860.710.60.410.12-0.020.720.780.92-0.040.730.770.240.150.750.520.220.920.870.720.47-0.39
-0.37-0.38-0.42-0.44-0.28-0.25-0.12-0.120.45-0.27-0.32-0.380.75-0.33-0.39-0.21-0.12-0.37-0.380.15-0.53-0.44-0.35-0.27-0.39
Click cells to compare fundamentals

Pharming Group Account Relationship Matchups

Pharming Group fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets255.6M419.1M396.9M425.8M462.9M486.0M
Short Long Term Debt Total58.1M162.2M161.6M166.7M171.5M180.1M
Other Current Liab20.3M58.8M32.0M42.3M51.8M54.4M
Total Current Liabilities114.1M77.0M46.7M59.7M78.0M46.5M
Total Stockholder Equity117.3M183.7M192.7M204.6M218.8M229.7M
Property Plant And Equipment Net16.3M21.7M33.1M39.1M33.5M35.1M
Current Deferred Revenue34.6M34.3M(44.4K)(56.2K)(64.7K)(61.4K)
Net Debt(16.1M)(43.3M)(30.1M)(40.6M)109.8M115.3M
Retained Earnings(333.4M)(317.5M)(269.4M)(256.4M)(265.3M)(278.5M)
Accounts Payable6.0M13.5M5.1M6.1M14.5M7.9M
Cash74.3M205.5M191.7M207.3M61.7M71.7M
Non Current Assets Total136.3M155.5M147.7M148.3M146.5M153.8M
Non Currrent Assets Other2.5M510.4K(303.4K)1.3M1.6M863.7K
Cash And Short Term Investments74.3M205.5M191.7M207.3M213.4M224.1M
Net Receivables26.3M19.2M15.9M19.6M32.1M33.7M
Common Stock Shares Outstanding67.4M68.3M70.1M70.7M657.0M689.9M
Liabilities And Stockholders Equity255.6M419.1M396.9M425.8M462.9M486.0M
Non Current Liabilities Total24.2M158.4M157.5M161.5M166.1M174.4M
Inventory16.2M21.2M27.3M42.3M56.8M59.6M
Other Current Assets2.6M5.0M2.6M2.5M13.8M14.4M
Other Stockholder Equity439.4M500.9M462.7M462.3M479.2M355.2M
Total Liab138.4M235.4M204.2M221.2M244.1M256.3M
Total Current Assets119.3M263.6M249.2M277.5M316.3M332.2M
Short Term Debt53.2M4.0M2.4M5.2M5.4M5.2M
Intangible Assets79.3M94.2M83.8M75.1M71.3M43.1M
Common Stock7.1M7.9M7.3M7.5M6.9M6.6M
Accumulated Other Comprehensive Income4.2M5.3M2.2M(8.7M)(2.1M)(2.0M)
Other Liab32.7M17.3M173K146K131.4K124.8K
Net Tangible Assets38.2M77.2M96.2M129.5M148.9M156.4M
Long Term Debt0.0121.9M122.6M131.6M136.6M95.7M
Capital Lease Obligations6.3M8.3M18.4M33.3M33.1M34.8M
Deferred Long Term Liab2.2M4.3M4.4M266K239.4K227.4K
Net Invested Capital150.3M273.0M294.5M338.0M357.2M258.8M
Short Long Term Debt45.6M1.7M1.7M1.8M1.8M1.7M
Non Current Liabilities Other32.0M17.3M173K146K131.4K124.8K
Net Working Capital4.6M151.8M178.8M217.8M238.4M134.2M
Property Plant Equipment14.5M17.6M29.3M39.1M45.0M47.3M

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.